Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.65 |
| ▸ | PREP | P48147 | 4/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | PRCP | P42785 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KLK7 | P49862 | 1/20 | 0.56 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14665154 | 0.96 | TSHR (0.61) | TSHRL3MBTL1PREPNPSR1KDM4E | |
| SCHEMBL8415456 | 0.96 | TSHR (0.61) | TSHRL3MBTL1PREPNPSR1KDM4E | |
| SCHEMBL13374867 | 0.88 | PREP (0.61) | TSHRL3MBTL1PREPNPSR1KDM4E | |
| SCHEMBL3560163 | 0.88 | PREP (0.61) | TSHRL3MBTL1PREPNPSR1KDM4E | |
| SCHEMBL29302756 | 0.87 | PREP (0.61) | TSHRL3MBTL1PREPNPSR1KDM4E | |
| SCHEMBL9555086 | 0.87 | PREP (0.61) | TSHRL3MBTL1PREPNPSR1KDM4E | |
| SCHEMBL13191519 | 0.87 | PREP (0.61) | TSHRL3MBTL1PREPNPSR1KDM4E | |
| SCHEMBL9555094 | 0.87 | PREP (0.61) | TSHRL3MBTL1PREPNPSR1KDM4E | |
| SCHEMBL47051 | 0.87 | PREP (0.61) | TSHRL3MBTL1PREPNPSR1KDM4E | |
| SCHEMBL14948306 | 0.87 | TSHR (0.62) | TSHRL3MBTL1PREPNPSR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383094-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-20100080772-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100080772-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | TSHR 4635/4885L3MBTL1 3763/4885PREP 2563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.